| Patent Number |
Title Of Patent |
Date Issued |
| 7256178 |
Physiologically active substances |
August 14, 2007 |
| Compounds represented by the following general formula (I), pharmacologically acceptable salts thereof or hydrates of the same: (I) wherein W represents ##STR00001## and R.sup.3, R.sup.7, R.sup.16, R.sup.17, R.sup.20, R.sup.21 and R.sup.21' are the same or different and each represe |
| 7247729 |
Method for producing pipecolamide derivative |
July 24, 2007 |
| A method of manufacturing a pipecolamide derivative, characterized in that pipecolic acid or an acid salt thereof is reacted with an amine in an inert solvent in the presence of a condensing agent such as dicyclohexylcarbodiimide, 1-ethyl-2-(2-dimethylaminopropyl)carbodiimide, methan |
| 7235388 |
Isolated nucleic acid encoding L-lysine: 2-oxoglutaric acid 6-aminotransferase |
June 26, 2007 |
| Provided are an isolated gene capable of participating in the production of L-homoglutamic acid, and a production system of L-homoglutamic acid by using this gene. The gene is derived from the genome of Flavobacterium lutescens. |
| 7115412 |
Process for the preparation of optically active 7-substituted-3-(2-aminopropyl)indole derivative |
October 3, 2006 |
| Disclosed are a process for preparation of an optically active 7-substituted 3-(2-aminopropyl)indole compound and an intermediate therefor. In the above preparation process, 7-substituted indole is reacted with L- or DL-serine in the presence of a tryptophan-synthesizing enzyme origi |
| 7060821 |
Osteoclast differentiation inhibitors |
June 13, 2006 |
| A compound represented by formula (I); a process for producing a compound (substance F-1490) of formula (I), wherein X represents --O-- and R represents a hydroxyl group, by using a microorganism belonging to the genus Cunninghamella; and a Cunninghamella sp. F-1490 strain (FERM BP-8 |
| 7026352 |
Physiologically active substances |
April 11, 2006 |
| The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution of S |
| 7022502 |
Process for the biological production of L-pipecolic acid |
April 4, 2006 |
| A process for the production of L-pipecolic acid which comprises the step of reducing delta-1-piperideine-6-carboxylic acid by the use of pyrroline-5-carboxylate reductase. The delta-1-piperideine-6-carboxylic acid is obtained by the step of converting L-lysine by the use of lysine 6 |
| 6900340 |
Preparation of isocoumarin derivatives and intermediates for the synthesis thereof |
May 31, 2005 |
| A method of preparing optically active isocoumarin-3-yl-acetic acid derivatives represented by Formula (I): ##STR1##wherein a specific isocoumarin-ketene derivative is subjected to an addition reaction with an optically active alcohol, and then the ester thus obtained is subjected to |
| 6890746 |
Gene participating in the production of homo-glutamic acid and utilization thereof |
May 10, 2005 |
| Provided are an isolated gene capable of participating in the production of L-homoglutamic acid, and a production system of L-homoglutamic acid by using this gene. The gene is derived from the genome of Flavobacterium lutescens. |
| 6747012 |
Crystalline anthracycline antibiotic and process for producing the same |
June 8, 2004 |
| Disclosed are a crystalline form of anthracycline antibiotic having specific characteristic 2.theta. values as measured by the X-ray diffraction method, and a process for producing the crystalline form. This process comprises the step of crystallization involving the combined use of |
| 6653455 |
Crystallization of doxorubicin hydrochloride |
November 25, 2003 |
| Disclosed are a crystallizing method of doxorubicin hydrochloride from a doxorubicin hydrochloride-containing solution, particularly a method for carrying out the crystallization under a condition of 40.degree. C. or higher, and a doxorubicin hydrochloride crystalline aggregate having |
| 6589981 |
Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives |
July 8, 2003 |
| A method for enhancing the efficacy of chemotherapy and/or radiation in the treatment of cancer in animals, particularly humans, is provided wherein certain isocoumarin derivatives which exhibit unique radiosensitization activity and/or chemopotentiation properties are employed in a comb |
| 6566394 |
Salicylamide derivatives |
May 20, 2003 |
| Salicylamide derivatives represented by formulae (1a) and (1b); intermediates in the production thereof; a process for producing the same; and drugs containing the same as the active ingredient. The salicylamide derivatives represented by formulae (1a) and (1b) are useful as anti-inf |
| 6548695 |
Process for producing isocoumarins and intermediates for the same |
April 15, 2003 |
| Provided is a process for producing an isocoumarin-3-yl-acetic acid derivative, characterized by reacting a homophthalic acid derivative represented by a formula: ##STR1##(wherein R.sub.c, R.sub.2 and R are mainly protecting groups) with a malonic acid derivating represented by a for |
| 6426420 |
Process for producing isocoumarines and intermediates for the same |
July 30, 2002 |
| Provided is a process for producing an isocoumarin-3-yl-acetic acid derivative, characterized by reacting a homophthalic acid derivative represented by a formula: ##STR1##(wherein R.sub.c, R.sub.2 and R are mainly protecting groups) with a malonic acid derivating represented by a for |
| 6410759 |
Dihydroxycholesterol hydroxylated at 17- and 25-positions |
June 25, 2002 |
| A method for preparing at least one hydroxycholesterol chosen from the group consisting of 25-hydroxycholesterol, 17,25-dihydroxycholesterol and 25,26-dihydroxycholesterol by biological hydroxylation of cholesterol, and the aforementioned dihydroxycholesterols. In the above biological |
| 6388058 |
Method of purifying daunomycin |
May 14, 2002 |
| The present invention relates to a method in which daunomycin is eluted from a hydrophobic porous synthetic resin carrier onto which daunomycin is adsorbed from crude daunomycin with a buffered aqueous solution containing a water-miscible organic solvent to recover purified daunomycin. |
| 6361987 |
Gene encoding a protein having asymmetric hydrolase activity for 4-substituted 1,4-dihydropyridi |
March 26, 2002 |
| This invention provides DNA fragments for efficiently preparing a protein having asymmetric hydrolase activity for 4-substituted 1,4-dihydropyridine derivatives, transformants obtained by using such a DNA fragment, and a process for preparing the aforesaid enzyme. Specifically, an isolat |
| 6146844 |
Process for producing hydroxylated cholesterols and dihydroxycholesterols using amycolata |
November 14, 2000 |
| A method for preparing at least one hydroxycholesterol chosen from the group consisting of 25-hydroxycholesterol, 17,25-dihydroxycholesterol and 25,26-dihydroxycholesterol by biological hydroxylation of cholesterol, and the aforementioned dihydroxycholesterols. In the above biological |
| 6143541 |
Gene encoding a protein having symmetric hydrolase activity for 4-substituted 1,4-dihydropyridin |
November 7, 2000 |
| This invention provides DNA fragments for efficiently preparing a protein having asymmetric hydrolase activity for 4-substituted 1,4-dihydropyridine derivatives, transformants obtained by using such a DNA fragment, and a process for preparing the aforesaid enzyme. Specifically, an isolat |
| 6133443 |
Optically active 1,4-dihydropyridine derivatives and process for the preparation thereof |
October 17, 2000 |
| Optically active 1,4-dihydropyridine derivatives represented by general formula (I) and anion salts thereof and a production method therefor: ##STR1## (wherein R.sup.1 represents a C.sub.1-6 alkyl group, R.sup.2 represents a nitrogen-containing heterocyclic group forming a quaternary |
| 6043050 |
Biological process for producing steroids hydroxylated at the 25-position |
March 28, 2000 |
| A biological process for producing steroids hydroxylated at the 25-position thereof comprises adding steroids (excluding cholesterol) to the cells or culture liquid of a microorganism of the genus Amycolata or Sphingomonas capable of hydroxylating the steroids at the 25-position thereof |
| 5906927 |
Process for producing L-2-aminoadipic acid |
May 25, 1999 |
| A process for producing L-2-aminoadipic acid, which comprises converting an aminomethyl group of L-lysine into a carboxyl group by use of a culture of a microorganism of the genus Flavobacterium. By this process, L-2-aminoadipic acid can be obtained directly from L-lysine in a high y |
| 5760238 |
1,4-dihydropyridine derivatives |
June 2, 1998 |
| Disclosed are 1,4-dihydropyridine derivatives represented by the general formula (I) and salts thereof, as well as optical active 1,4-dihydropyridine derivatives represented by the general formula (II) and salts thereof which are obtained from the derivative by biochemical reactions |
| 5395941 |
Optically active 1,4-hydropyridine compounds |
March 7, 1995 |
| Optically active 1,4-dihydropyridine derivatives represented by general formula (I), process for preparing compounds (Ic) (in general formula (I) , R.sup.1 is a lower alkyl group), process for preparing compounds represented by general formula (II) by hydrolyzing the compounds (Ic) u |
| 5376537 |
Process for production of cyclodextrins |
December 27, 1994 |
| A process for the production of cyclodextrins, comprising reacting non-treated starch with cyclodextrin-glycosyl-transferase produced by Bacillus ohbensis (FERM BP-3180), or produced by a mutant derived from Bacillus ohbensis (e.g., FERM BP-3180), or produced by any other strain in w |
| 5322937 |
Genes encoding a 3-acylation enzyme for macrolide antibiotics |
June 21, 1994 |
| A DNA fragment or a restriction enzyme-digested DNA fragment, the DNA fragment containing a gene, acyA, encoding a 3-acylation enzyme for macrolide antibiotics, characterized by being derived from a strain belonging to the genus Streptomyces, having a size of about 1.8 kb or about 3. |
| 5252304 |
Formalin sterilization apparatus |
October 12, 1993 |
| A reaction chamber is disposed between a heating chamber and an outlet line of the heating chamber, and performs a reaction of ammonia gas vaporized in the heating chamber with formaldehyde circulated from a room to be sterilized. A filter is disposed between the reaction chamber and the |
| 5232943 |
Antibiotics Mer-AF1032A and Mer-AF1032B |
August 3, 1993 |
| Antibiotic Mer-AF1032A represented by the following formula (I) and its isomer antibiotic Mer-AF1032B are disclosed. Also disclosed are a method for preparing the antibiotics comprising the cultivation of a strain belonging to genus Penicillium and a pharmaceutical composition comprising |
| 5223519 |
4-hydroxypyridine derivatives, useful for treating circulatory diseases |
June 29, 1993 |
| 4-Hydroxypyridine derivative represented by the following formula ##STR1## wherein R represents a methyl group or an isopropyl group, and the method for preparing the derivative comprising the step of cultivating a strain belonging to Streptomyces karnatakensis are disclosed. Also di |
| 5183883 |
Conjugate of adriamycin and cyclodextrin |
February 2, 1993 |
| Adriamycin derivatives represented by formula (I) ##STR1## wherein R denotes a divalent hydrocarbon group,CD denotes a cyclodextrin residue,m is 1 to 8, andn is 0 to 8.The compounds exhibit excellent anti-cancer activity over a wide administration range, have low toxicity and sustained r |
| 5149802 |
Process for producing azetidinone derivatives |
September 22, 1992 |
| A process for producing 2-azetidinone derivatives represented by formula ##STR1## wherein R.sup.1 denotes a protecting group of a hydroxyl group,Z denotes a hydrogen atom or a protecting group of an amino group, andQ denotes ##STR2## in which X denotes a halogen atom, Y denotes a ha |
| 5132136 |
Condensed wine composition for cooking and method of preparing the same |
July 21, 1992 |
| A condensed wire composition containing an extract content of no less than 18% (w/v) is obtained by vacuum condensing a wine at a temperature of 5.degree. to 60.degree. C., preferably 20.degree. to 35.degree. C. to a concentration by at least 8 times as high as the original, retaining th |
